Login Register Cart 0
Generic placeholder image

Current Chromatography

Editor-in-Chief

ISSN (Print): 2213-2406
ISSN (Online): 2213-2414

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Implementation of Quality by Design Approach for Optimization of RP-HPLC Method for Quantification of Abiraterone Acetate in Solid Dispersion in Forced Degradation Studies

Author(s): Manisha Choudhari, Mahipal Reddy Donthi, Shantanu Damle, Gautam Singhvi, Ranendra Narayan Saha and Sunil Kumar Dubey*

Volume 9, Issue 1, 2022

Published on: 02 December, 2022

Article ID: e101122210756 Pages: 17

DOI: 10.2174/2213240609666221110090339

Price: $65

Abstract

Background: Abiraterone acetate is a derivative of steroidal progesterone, used as a firstline therapy for metastatic castration of prostate cancer.

Objectives: The present study encompasses the design of an experiment approach for developing a simple, reliable, and rapid RP-HPLC method for the estimation of abiraterone acetate.

Methods: The chromatographic separation was efficiently conducted on a Hypersil Gold C18 (50 x 4.6 mm, 5 μm) HPLC column, using the mobile phase composition of acetonitrile: dibasic potassium phosphate (0.01 mM) in the ratio of 80:20 (%v/v) at pH 6.5 with an isocratic elution mode. Furthermore, the different force degradation study including hydrolysis, oxidation, thermal, and photolytic was performed for abiraterone acetate.

Results: The dynamic linearity was established in the concentration range of 0.5-10 μg/mL with r2 of 0.9998. Furthermore, the limit of detection and the limit of quantitation were 0.0978 μg/mL and 0.3260 μg/mL. The degradation of abiraterone acetate was shown in both acidic (54.16 ± 0.247 after 24 hrs) and basic conditions (35.06 ± 0.458 after 24 hrs). Furthermore, the developed method was successfully employed to quantify abiraterone acetate in bulk powder and the solid dispersion did not show any change in the retention time.

Conclusion: The developed method was validated according to the ICH Q2 (R1) specification, which was found to be sensitive, accurate, precise, robust, linear, and selective compared to the reported chromatographic method.

Graphical Abstract

[1]
Beckett, R.D.; Rodeffer, K.M.; Snodgrass, R. Abiraterone for the treatment of metastatic castrate-resistant prostate cancer. Ann. Pharmacother., 2012, 46(7-8), 1016-1024.
[http://dx.doi.org/10.1345/aph.1Q758] [PMID: 22714819]
[2]
Thakur, A.; Roy, A.; Ghosh, A.; Chhabra, M.; Banerjee, S. Abiraterone acetate in the treatment of prostate cancer. Biomed. Pharmacother. Biomed. Pharmacotherapie, 2018, 101, 211-218.
[3]
Heidegger, I.; Massoner, P.; Eder, I.E.; Pircher, A.; Pichler, R.; Aigner, F.; Bektic, J.; Horninger, W.; Klocker, H. Novel therapeutic ap-proaches for the treatment of castration-resistant prostate cancer. J. Steroid Biochem. Mol. Biol., 2013, 138, 248-256.
[http://dx.doi.org/10.1016/j.jsbmb.2013.06.002] [PMID: 23792785]
[4]
Rebello, S.; Asok, A.K.; Mundayoor, S.; Jisha, M. Surfactants: chemistry, toxicity and remediation. In: Pollutant Diseases, Remediation and Recycling; Springer, 2013, pp. 277-320.
[http://dx.doi.org/10.1007/978-3-319-02387-8_5]
[5]
Thorat, Y.S.; Gonjari, I.D.; Hosmani, A.H. Solubility enhancement techniques: A review on conventional and novel approaches. Int. J. Pharm. Sci. Res., 2011, 2(10), 2501.
[6]
Huang, Y.; Dai, W-G. Fundamental aspects of solid dispersion technology for poorly soluble drugs. Acta Pharm. Sin. B, 2014, 4(1), 18-25.
[http://dx.doi.org/10.1016/j.apsb.2013.11.001] [PMID: 26579360]
[7]
Kumar, S.V.; Rudresha, G.; Gurav, S.; Zainuddin, M.; Dewang, P.; Kethiri, R.R.; Rajagopal, S.; Mullangi, R. Validated RP-HPLC/UV meth-od for the quantitation of abiraterone in rat plasma and its application to a pharmacokinetic study in rats. Biomed. Chromatogr., 2013, 27(2), 203-207.
[http://dx.doi.org/10.1002/bmc.2776] [PMID: 22763809]
[8]
Martins, V.; Asad, Y.; Wilsher, N.; Raynaud, F. A validated liquid chromatographic-tandem mass spectroscopy method for the quantifica-tion of abiraterone acetate and abiraterone in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2006, 843(2), 262-267.
[http://dx.doi.org/10.1016/j.jchromb.2006.06.010] [PMID: 16809076]
[9]
Belleville, T.; Noé, G.; Huillard, O.; Thomas-Schoemann, A.; Vidal, M.; Goldwasser, F.; Alexandre, J.; Blanchet, B. A HPLC-fluorescence method for the quantification of abiraterone in plasma from patients with metastatic castration-resistant prostate cancer. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2015, 989, 86-90.
[http://dx.doi.org/10.1016/j.jchromb.2015.03.001] [PMID: 25813901]
[10]
Fukuda, I.M.; Pinto, C.F.F.; Moreira, C.S.; Saviano, A.M.; Lourenço, F.R. Design of experiments (DoE) applied to pharmaceutical and analytical quality by design (QbD). Braz. J. Pharm. Sci., 2018, 54(spe), 54.
[http://dx.doi.org/10.1590/s2175-97902018000001006]
[11]
Peraman, R.; Bhadraya, K.; Padmanabha Reddy, Y. Analytical quality by design: A tool for regulatory flexibility and robust analytics. Int. J. Anal. Chem., 2015, 2015868727
[http://dx.doi.org/10.1155/2015/868727]
[12]
Jadhav, M.L.; Tambe, S.R. Implementation of QbD approach to the analytical method development and validation for the estimation of propafenone hydrochloride in tablet dosage form. Chromatogr. Res. Int., 2013, 2013676501
[http://dx.doi.org/10.1155/2013/676501]
[13]
Singh, B.; Kumar, R.; Ahuja, N. Optimizing drug delivery systems using systematic design of experiments.” Part I: fundamental aspects. Critical ReviewsTM in Therapeutic Drug Carrier Systems., 2005, 22(1), 27-105.
[14]
Politis, S.N.; Colombo, P.; Colombo, G.; Rekkas, M. D. Design of experiments (DoE) in pharmaceutical development. Drug Dev. Ind. Pharm., 2017, 43(6), 889-901.
[http://dx.doi.org/10.1080/03639045.2017.1291672] [PMID: 28166428]
[15]
Jain, A.; Sharma, T.; Sharma, G.; Khurana, R.K.; Katare, O.P.; Singh, B. QbD-driven analytical method development and validation for raloxifene hydrochloride in pure drug and solid oral dosage form. Anal. Chem. Lett., 2019, 9(4), 463-477.
[http://dx.doi.org/10.1080/22297928.2019.1624193]
[16]
Pradhan, R.; Krishna, K.; Wadhwa, G.; Taliyan, R.; Khadgawat, R.; Kachhawa, G.; Singhvi, G.; Dubey, S.K. QbD-driven development and validation of HPLC method for determination of Bisphenol A and Bis-sulphone in environmental samples. Int. J. Environ. Anal. Chem., 2020, 100(1), 42-54.
[http://dx.doi.org/10.1080/03067319.2019.1629585]
[17]
Guideline, I. H. T. Validation of analytical procedures: text and methodology. 2005, 1(20), 05.
[18]
Bhatt, D.; Thatavarthi, R.; Rajkamal, B. Analytical method development and validation for the estimation of canagliflozin in bulk and for-mulation by RP-HPLC. Int. J. Pharm. Sci. Drug Res., 2018, 10(3), 139-143.
[http://dx.doi.org/10.25004/IJPSDR.2018.100306]
[19]
Kumar, P.A.; Thirupathi, D.; Kumar, Y.R.; Jayashree, A. simultaneous determination of related organic impurities of ibuprofen and para-cetamol in combination solid dosage form by rp‐hplc with qbd approach. Orient. J. Chem., 2017, 33(3), 1461-1468.
[http://dx.doi.org/10.13005/ojc/330349]
[20]
Krishna, K.V.; Saha, R.N.; Singhvi, G.; Dubey, S.K. Pre-clinical pharmacokinetic-pharmacodynamic modelling and biodistribution studies of donepezil hydrochloride by a validated HPLC method. RSC Advances, 2018, 8(44), 24740-24749.
[http://dx.doi.org/10.1039/C8RA03379J]
[21]
Rignall, A. ICHQ1A (R2) stability testing of new drug substance and product and ICHQ1C stability testing of new dosage forms.In: Teas-dale, A.; Elder, D.; Nims, R.W. ICH quality guidelines: an implementation guide; Wiley, 2017, pp. 3-44.
[22]
Blessy, M.; Patel, R.D.; Prajapati, P.N.; Agrawal, Y.K. Development of forced degradation and stability indicating studies of drugs-A re-view. J. Pharm. Anal., 2014, 4(3), 159-165.
[http://dx.doi.org/10.1016/j.jpha.2013.09.003] [PMID: 29403878]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy